{"id":"W2168482167","doi":"10.1158/1078-0432.ccr-03-0244","title":"Treatment of HER-2/<b> <i>neu</i> </b> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/<b> <i>neu</i> </b> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"Stemcell Technologies; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Gefitinib; Trastuzumab; Medicine; Cancer research; Epidermal growth factor receptor; In vivo; Estrogen receptor; Breast cancer; Growth inhibition; Cell growth; Cancer; Internal medicine; Pharmacology; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002003775,0.000547687,0.0008262143,0.0002742389,0.0001913908,0.0002564337,0.0003553327,0.000354862,0.001082512],"category_scores_gemma":[0.0000936654,0.0001872174,0.00036559,0.0001787767,0.0001417885,0.0002702619,0.0001346115,0.0006880974,0.0002461504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004108486,"about_ca_system_score_gemma":0.0002979394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008523039,"about_ca_topic_score_gemma":0.002182712,"domain_scores_codex":[0.9998276,0.00002665773,0.00001750138,0.00003703778,0.00004867465,0.00004248079],"domain_scores_gemma":[0.9998873,0.00001561736,0.00002896272,0.00001335945,0.00001258458,0.00004207031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001047255,0.0006400659,0.000450476,0.0000596475,0.00002561476,0.00003383368,0.00001112156,0.0002006276,0.9949358,0.00002113436,0.0001216323,0.002452868],"study_design_scores_gemma":[0.0001950311,0.006321674,0.005141771,0.000004870948,0.00005800588,0.0003081049,0.00001920365,0.000936792,0.9855876,0.00001255898,0.001405129,0.000009204438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969627,0.001306019,0.0005249599,0.00007190014,0.00004507117,0.00006022126,0.0003399157,0.00005756236,0.000631633],"genre_scores_gemma":[0.9922388,0.001489303,0.00330058,0.00005381194,0.00003017497,0.0001131805,0.0009224778,0.00002637299,0.001825258],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001082512,"threshold_uncertainty_score":0.00362134,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08032479363375436,"score_gpt":0.4131441111757406,"score_spread":0.3328193175419862,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}